9.93
+0.1(+1.02%)
Currency In USD
| Previous Close | 9.83 |
| Open | 9.96 |
| Day High | 10.33 |
| Day Low | 9.85 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 709,826 |
| Average Volume | 965,618 |
| Market Cap | 759.14M |
| PE | -3.82 |
| EPS | -2.6 |
| Moving Average 50 Days | 9.66 |
| Moving Average 200 Days | 12.81 |
| Change | 0.1 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $522.36 as of October 08, 2025 at a share price of $9.93. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $903.55 as of October 08, 2025 at a share price of $9.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Con
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
Regulatory momentum builds for bexobrutideg with multiple designations across the United States and EU, Including EMA PRIME and FDA Fast Track for CLL/SLLSAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a cl
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforce